

Editor

Leo van de Putte (The Netherlands)

Associate editors

Thomas Bardin (France)
Johannes Bijlsma (The Netherlands)
Gerd Burmester (Germany)

Bevrah Hahn (USA)
Frank Wollheim (Sweden)
Anthony Woolf (UK)

Methodological adviser

Jaap Fransen (The Netherlands)

Editorial board

M Aringer (Austria)
P Bacon (UK)
F Berenbaum (France)
M Boers (The Netherlands)
D Boumpas (Greece)
B Bresnihan (Ireland)
H Capell (UK)
M Cutolo (Italy)
G Firestein (USA)
P Goupille (France)
E Gravallesse (USA)
W Gross (Germany)
F Guillemin (France)
G Herrero-Beaumont (Spain)
F Houssiau (Belgium)
T Huizinga (The Netherlands)
C Jorgensen (France)
G Kollias (Greece)
T Kvien (Norway)
M Leirisalo-Repo (Finland)
F Luijten (Belgium)
H-M Lorenz (Germany)
W Maslinski (Poland)
M Matucci Cerinic (Italy)

K Nishioka (Japan)
M Nurmohamed (The Netherlands)
S Özen (Turkey)
T Pap (Germany)
E Pascual Gómez (Spain)
L Punzi (Italy)
L Rönnblom (Sweden)
B Rozman (Slovenia)
G Schett (Austria)
J Da Silva (Portugal)
H Schulze-Koops (Germany)
A So (Switzerland)
T Sokka (USA)
D Symmons (UK)
P-P Tak (The Netherlands)
A Tyn dall (Switzerland)
A Tzioufas (Greece)
J Vencovsky (Czech Republic)
M Ward (USA)
M Weisman (USA)
H Yazici (Turkey)
Editor, *BMJ*

Advisory committee

W vd Berg (The Netherlands)
S Bombardieri (Italy)
F Breedveld (The Netherlands)
L Crofford (USA)
J-M Dayer (Switzerland)
M Doherty (UK)
M Dougados (France)
J Edmonds (Australia)
P Emery (UK)
D Furst (USA)
S Gay (Switzerland)
J Kalden (Germany)
E Keystone (Canada)
L Klareskog (Sweden)

P Lipsky (USA)
S Lohmander (Finland)
R Maini (UK)
E M Mola (Spain)
H Moutsopoulos (Greece)
J O'Dell (USA)
K Pavelka (Czech Republic)
J Rovensky (Slovakia)
Y Shoenfeld (Israel)
J Smolen (Austria)
W van Venrooy (The Netherlands)
E Veys (Belgium)
A Wiik (Denmark)

Guidelines for authors and reviewers

Guidance for authors and reviewers can be found at <http://ard.bmj.com/fora>
All papers must be submitted via Bench>Press at www.submit-ard.bmj.com

Disclaimer

Annals of the Rheumatic Diseases is published by BMJ Publishing Group Ltd, a wholly owned subsidiary of the British Medical Association, and the European League Against Rheumatism.

The BMA grants editorial freedom to the Editor of the *Annals of the Rheumatic Diseases*. The *Annals of the Rheumatic Diseases* follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

The *Annals of the Rheumatic Diseases* is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group, The European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement. To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of the *Annals of the Rheumatic Diseases* or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Subscription information

See p iv
ISSN 0003-4967 (print); 1468-2060 (online)


Copyright

© 2007 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of *Annals of the Rheumatic Diseases*

Authors are required to grant *Annals of the Rheumatic Diseases* an exclusive licence to publish; further details available online at <http://annrheumdis.com/fora/licence.dtl>

• *Annals of the Rheumatic Diseases* is published by BMJ Publishing Group, copyedited by Macmillan India Ltd, typeset by The Charlesworth Group, and printed in the UK on acid-free paper by Cambrian Printers Limited, Aberystwyth

• Periodicals postage paid, Rahway, NJ. Postmaster: send address changes to: *Annals of the Rheumatic Diseases*, c/o Mercury Airfreight International Ltd, 365 Blair Road, Avenel, NJ 07001, USA



TGF β -regulated MMP-3 expression in synovial fibroblasts. See p446

Editorial

429 Is there a microangiopathic antiphospholipid syndrome? *R A Asherson, S Pierangeli, R Cervera*

Reviews

433 Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis *R Christensen, E M Bartels, A Astrup, H Bliddal*

440 Management of septic arthritis: a systematic review *C J Mathews, G Kingsley, M Field, A Jones, V C Weston, M Phillips, D Walker, G Coakley*

Extended reports

446 Attachment to laminin-111 facilitates transforming growth factor β -induced expression of matrix metalloproteinase-3 in synovial fibroblasts *M Hoberg, M Rudert, T Pap, G Klein, S Gay, W K Aicher*

452 GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice *C Plater-Zyberk, L A B Joosten, M M A Helsen, J Hepp, P A Baeuerle, W B van den Berg*

458 Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum *L Šenolt, D Housa, Z Vernerová, T Jirásek, R Svobodová, D Veigl, K Anderlová, U Müller-Ladner, K Pavelka, M Haluzik*

464 Reproducibility and sensitivity to change of four scoring methods for the radiological assessment of osteoarthritis of the hand *E Maheu, C Cadet, S Gueneugues, P Ravaut, M Dougados*

470 Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system *M Tokunaga, K Saito, D Kawabata, Y Imura, T Fujii, S Nakayamada, S Tsujimura, M Nawata, S Iwata, T Azuma, T Mimori, Y Tanaka*

476 Reduced telomere length in rheumatoid arthritis is independent of disease activity and duration *S E Steer, F M K Williams, B Kato, J P Gardner, P J Norman, M A Hall, M Kimura, R Vaughan, A Aviv, T D Spector*

481 Sulphasalazine inhibits human antigen-specific immune responses in vivo *C Trollmo, S Gudmundsson, N Feltelius, S Rogberg, G Smedegård, L Klareskog*

486 Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register *T M Farragher, M Lunt, D K Bunn, A J Silman, D P M Symmons*

493 Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate *J Gratacós, E Casado, J Real, J C Torre-Alonso*



www.publicationethics.org.uk

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

- 498 Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial
A Kavanaugh, G G Krueger, A Beutler, C Guzzo, B Zhou, L T Dooley, P J Mease, D D Gladman, K de Vlam, P P Geusens, C Birbara, D G Halter, C Antoni, for the IMPACT 2 Study Group
- 506 Cardiac dysfunction in patients with systemic lupus erythematosus and antiphospholipid syndrome
D Paran, D Caspi, D Levarovsky, O Elkayam, I Kaufman, I Litinsky, G Keren, B Koifman
- 511 Anti-cyclic citrullinated peptide positivity in non-rheumatoid arthritis disease samples: citrulline-dependent or not?
A Vannini, K Cheung, M Fusconi, J Stammen-Vogelzangs, J P H Drenth, A C Dall'Aglio, F B Bianchi, L E Bakker-Jonges, W J van Venrooij, G J M Pruijn, A J W Zendman
- 517 Pressure pain thresholds and tender point counts as predictors of new chronic widespread pain in somatising subjects
A Gupta, J McBeth, G J Mactarlane, R Morriss, C Dickens, D Ray, Y H Chiu, A J Silman
- 522 Diagnostic quality and scoring of synovitis, tenosynovitis and erosions in low-field MRI of patients with rheumatoid arthritis: a comparison with conventional MRI
C Schirmer, A K Scheel, C E Althoff, T Schink, I Eshed, A Lembcke, G-R Burmester, M Backhaus, B Hamm, K-G A Hermann
-
- Concise reports**
- 530 Cell-ELISA detection of antineuronal antibodies in central nervous system involvement in systemic lupus erythematosus
X Zhang, H Shu, F Zhang, X Tian, Y Dong
- 533 Factor XII autoantibodies as a novel marker for thrombosis and adverse obstetric history in patients with systemic lupus erythematosus
M L Bertolaccini, K Mepani, G Sanna, G R V Hughes, M A Khamashta
- 537 High anti-collagen type-II antibody levels and induction of proinflammatory cytokines by anti-collagen antibody-containing immune complexes in vitro characterise a distinct rheumatoid arthritis phenotype associated with acute inflammation at the time of disease onset
M Mullazehi, L Mathsson, J Lampa, J Rönnelid
- 542 Formative research in clinical trial development: attitudes of patients with arthritis in enhancing prevention trials
H A Taylor, J Sugarman, D S Pisetsky, J Bathon
- 545 Real-time quantitative PCR to detect changes in synovial gene expression in rheumatoid arthritis after corticosteroid treatment
D M Gerlag, D L Boyle, S Rosengren, T Nash, P P Tak, G S Firestein
- 548 Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis
P Tynjälä, P Lindahl, V Honkanen, P Lahdenne, K Kotaniemi
- 551 Risk factors for lung cancer in patients with scleroderma: a nested case-control study
E K Pontifex, C L Hill, P Roberts-Thomson
- 554 Vasculitis restricted to the lower limbs: a clinical and histopathological study
M Khellaf, M Hamidou, C Pagnoux, M Michel, J M Brisseau, X Chevallier, P Cohen, L Guillevin, B Godeau
-
- Letters**
- 557 Will steroidal aromatase inhibitors induce rheumatoid arthritis?
B Morel, H Marotte, P Miossec
- 558 Improved insulin sensitivity by anti-TNF α antibody treatment in patients with rheumatic diseases
F C Huvers, C Popa, M G Netea, F H J van den Hoogen, C J Tack
- 560 Study of DNASE I gene polymorphisms in systemic lupus erythematosus susceptibility
A Bodaño, A González, E Balada, J Ordi, P Carreira, J J Gómez-Reino, C Conde
- 561 High disease activity of ankylosing spondylitis in the community before the introduction of tumour necrosis factor blockers
J Hermann, T Müller, B Yazdani-Biuki, M Aringer, M Herold, W Ebner, P Ofner, W Graninger
- 562 Association of tumour necrosis factor α promoter polymorphisms with ankylosing spondylitis in Taiwan
M-Y Shiau, M-K Lo, C-P Chang, T-P Yang, K-T Ho, Y-H Chang
- 564 Infliximab in patients with systemic vasculitis that is difficult to treat: poor outcome and significant adverse effects
S R Sangle, G R V Hughes, D P D'Cruz
- 565 Adalimumab: a new modality for Behçet's disease?
J A M van Laar, T Missotten, P L A van Daele, A Jammitski, G S Baarsma, P M van Hagen
- 566 Autosplenectomy: rare syndrome in autoimmuneopathy
J Leipe, A J Hueber, S Kallert, J Rech, H Schulze-Koops
-
- 568 Forthcoming events